Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Adductor Canal Block: Efficacy in Postoperative Pain Management for Cardiac Surgery (AddEase)

23. juli 2026 opdateret af: Montreal Heart Institute

Effectiveness of Adductor Canal Block in Postoperative Co-analgesia for Cardiac Surgery With Saphenous Vein Harvesting

Adductor Canal Block: Efficacy in Postoperative Pain Management for Cardiac Surgery

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

120

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Quebec
      • Montreal, Quebec, Canada, H1T 1C8

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Planned CABG with unilateral or bilateral great saphenous vein (GSV) harvesting, without concomitant valve surgery
  • Age ≥ 18 years
  • Ability to understand the protocol and provide written informed consent
  • ASA physical status I-IV

Exclusion Criteria:

  • Refusal to participate in the study or inability to provide written informed consent
  • Contraindication to adductor canal block (e.g., local infection, allergy to local anesthetics)
  • Pre-existing chronic pain associated with chronic use of analgesic medications other than acetaminophen
  • Pre-existing peripheral neuropathy affecting the leg
  • Participation in two other interventional studies at the Montreal Heart Institute
  • Endoscopic vein harvesting performed by the surgical team instead of open saphenectomy technique

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Adductor canal bloc with bupivacaine + dexmedetomidine
Adductor canal bloc with 0,25% bupivacaine + 20 ucg of dexmedetomidine
Andre navne:
  • Pain relief arm
Placebo komparator: Control arm
Saline solution
Needle insertion mimicking the ACB procedure with injection of a saline solution

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Leg Pain at Rest
Tidsramme: Numeric rating scale (NRS 0-10) will be performed at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.

The primary outcome will be leg pain at rest, measured using a numeric rating scale (NRS 0-10) at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

Numeric rating scale (NRS 0-10) will be performed at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Total opioid consumption
Tidsramme: The first 48 postoperative hours after procedure
Cumulative amount administered, expressed in morphine milligram equivalents (MME), during the first 48 postoperative hours (conversion factors used: hydromorphone 1 mg = morphine 5 mg; fentanyl 100 µg = morphine 10 mg).
The first 48 postoperative hours after procedure
Postoperative pain unrelated to the saphenous territory
Tidsramme: Numeric rating scale (NRS 0-10) performed at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.

Incidence and characterization of postoperative pain unrelated to the saphenous territory (e.g., thoracic or musculoskeletal pain), assessed at the same time points as saphenous pain using a numeric rating scale (NRS 0-10).

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

Numeric rating scale (NRS 0-10) performed at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.
Persistent Postoperative Pain
Tidsramme: At 3 and 6 months postoperatively, assessed using the NRS.

Proportion of patients reporting pain ≥4/10 at the harvest site at 3 and 6 months postoperatively, assessed using the NRS.

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

At 3 and 6 months postoperatively, assessed using the NRS.
Overall persistent postoperative pain
Tidsramme: At 3 and 6 months postoperatively.

Proportion of patients reporting pain ≥4/10 (all sites combined) at 3 and 6 months postoperatively.

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

At 3 and 6 months postoperatively.
Presence of hypoesthesia
Tidsramme: Numeric rating scale at 3 and 6 months.

Presence of hypoesthesia (non-painful) at the saphenectomy site at 3 and 6 months using a numeric rating scale (NRS 0-10).

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

Numeric rating scale at 3 and 6 months.
Neuropathic characterization
Tidsramme: At 48 hours, 3 months, and 6 months.

Quantification of the modified DN4 score at the harvest site at 48 hours, 3 months, and 6 months.

Modified DN4 ≥ 3/8: high probability of neuropathic pain Modified DN4 < 3/8: neuropathic pain unlikely

At 48 hours, 3 months, and 6 months.
Block safety
Tidsramme: Assessed daily during hospitalization until patient is discharge from the hospital (an average of 7 days), up to 60 days.
Number of adverse events related to the adductor canal block observed during the hospital stay, including hematoma, infection, nerve injury, cardiovascular complications, motor block, and signs of local anesthetic systemic toxicity.
Assessed daily during hospitalization until patient is discharge from the hospital (an average of 7 days), up to 60 days.
Opioid-related side effects
Tidsramme: Each time the patient takes opioids during in the postoperative period until discharge from the hospital (an average of 7 days), up to 60 days.
Incidence of common opioid-related side effects in each group, including nausea, vomiting, and constipation.
Each time the patient takes opioids during in the postoperative period until discharge from the hospital (an average of 7 days), up to 60 days.
Time to extubation
Tidsramme: At extubation
Time to extubation after adductor canal block
At extubation

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Use of co-analgesia
Tidsramme: Assessed once daily total co-analgesic doses administered, until discharge (an average of 7 days), up to 60 days.
Number of treatments used and frequency of use (lidocaine-ketamine cream, NSAIDs, gabapentinoids, etc.)
Assessed once daily total co-analgesic doses administered, until discharge (an average of 7 days), up to 60 days.
Postoperative quality of life
Tidsramme: At 3 and 6 months postoperatively

EQ-5D score quantification measured at 3 and 6 months postoperatively. The EQ-5D (EuroQol - 5 Dimensions) is a standardized and validated instrument used to assess health-related quality of life across two components. It is widely used in clinical research to measure the overall impact of a medical intervention on patients' functional status and well-being.

It explores five dimensions of health:

  • Mobility
  • Self-care
  • Usual activities
  • Pain / discomfort
  • Anxiety / depression

Each dimension is assessed across 5 levels of severity:

  • No problems
  • Slight problems
  • Moderate problems
  • Severe problems
  • Extreme problems / inability

The combination of responses generates a 5-digit health profile, which can be converted into an EQ-5D index.

1.0: Represents perfect health. 0.0: Represents a state considered equivalent to death. Negative values: Health states deemed "worse than death."

At 3 and 6 months postoperatively
Opioid use
Tidsramme: At 3 and 6 months postoperatively
Opioid use at 3 and 6 months postoperatively, assessed by the presence or absence of opioid use and the type of opioid used.
At 3 and 6 months postoperatively

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. august 2026

Primær færdiggørelse (Anslået)

31. december 2027

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

2. juni 2026

Først indsendt, der opfyldte QC-kriterier

23. juli 2026

Først opslået (Faktiske)

29. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

23. juli 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Individual participant data (IPD) will not be shared, as study documents are available only in French. However, upon reasonable request, the investigators will provide the study protocol, informed consent form, statistical analysis plan, and any other relevant documents.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner